Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains.
BACKGROUND
Meningeal and other trigeminal nociceptors are thought to play important roles in the initiation of migraine headache. Currently, the only approved peripherally administered chronic migraine prophylactic drug is onabotulinumtoxinA. The purpose of this study was to determine how botulinum neurotoxin type A (BoNT-A) affects naïve and sensitized meningeal nociceptors.


METHODS
Using electrophysiological techniques, we identified 43 C- and 36 Aδ-meningeal nociceptors, and measured their spontaneous and evoked firing before and after BoNT-A administration to intracranial dura and extracranial suture-receptive fields.


RESULTS
As a rule, BoNT-A inhibited C- but not Aδ-meningeal nociceptors. When applied to nonsensitized C-units, BoNT-A inhibited responses to mechanical stimulation of the dura with suprathreshold forces. When applied to sensitized units, BoNT-A reversed mechanical hypersensitivity. When applied before sensitization, BoNT-A prevented development of mechanical hypersensitivity. When applied extracranially to suture branches of intracranial meningeal nociceptors, BoNT-A inhibited the mechanical responsiveness of the suture branch but not dural axon. In contrast, BoNT-A did not inhibit C-unit responses to mechanical stimulation of the dura with threshold forces, or their spontaneous activity.


CONCLUSIONS
The study provides evidence for the ability of BoNT-A to inhibit mechanical nociception in peripheral trigeminovascular neurons. These findings suggest that BoNT-A interferes with neuronal surface expression of high-threshold mechanosensitive ion channels linked preferentially to mechanical pain by preventing their fusion into the nerve terminal membrane.
Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School, Boston, MA, USA.
Rami
R
Burstein
Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School, Boston, MA, USA.
XiChun
X
Zhang
Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School, Boston, MA, USA.
Dan
D
Levy
Allergan Inc., Irvine, CA, USA.
K Roger
KR
Aoki
Allergan Inc., Irvine, CA, USA University of California, Irvine, CA, USA Brin_Mitchell@Allergan.com.
Mitchell F
MF
Brin
D000818:Animals; D019274:Botulinum Toxins, Type A / Q000494:pharmacology*; D004594:Electrophysiology; D008297:Male; D040542:Mechanotransduction, Cellular / Q000502:physiology; D008578:Meninges / Q000187:drug effects*; D008839:Microelectrodes; D008881:Migraine Disorders / Q000503:physiopathology*; D009498:Neurotoxins / Q000494:pharmacology*; D009619:Nociceptors / Q000187:drug effects*; D010146:Pain / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley
D009498:Neurotoxins; D019274:Botulinum Toxins, Type A
Pain; TRPA1; TRPV1; headache; high-threshold mechanosensitive ion channels; nociception